Literature DB >> 28719060

Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

B Jacka1, B C Bray2, T L Applegate1, B D L Marshall3, V D Lima4,5, K Hayashi4,6, K DeBeck4,7, J Raghwani8, P R Harrigan4,5, M Krajden9, J S G Montaner4,5, J Grebely1.   

Abstract

This study estimated latent classes (ie, unobserved subgroups in a population) of people who use drugs in Vancouver, Canada, and examined how these classes relate to phylogenetic clustering of hepatitis C virus (HCV) infection. HCV antibody-positive people who use drugs from two cohorts in Vancouver, Canada (1996-2012), with a Core-E2 sequence were included. Time-stamped phylogenetic trees were inferred, and phylogenetic clustering was determined by time to most common recent ancestor. Latent classes were estimated, and the association with the phylogenetic clustering outcome was assessed using an inclusive classify/analyse approach. Among 699 HCV RNA-positive participants (26% female, 24% HIV+), recent drug use included injecting cocaine (80%), injecting heroin (70%), injecting cocaine/heroin (ie, speedball, 38%) and crack cocaine smoking (28%). Latent class analysis identified four distinct subgroups of drug use typologies: (i) cocaine injecting, (ii) opioid and cocaine injecting, (iii) crack cocaine smoking and (iv) heroin injecting and currently receiving opioid substitution therapy. After adjusting for age and HIV infection, compared to the group defined by heroin injecting and currently receiving opioid substitution therapy, the odds of phylogenetic cluster membership was greater in the cocaine injecting group (adjusted OR [aOR]: 3.06; 95% CI: 1.73, 5.42) and lower in the crack cocaine smoking group (aOR: 0.06; 95% CI: 0.01, 0.48). Combining latent class and phylogenetic clustering analyses provides novel insights into the complex dynamics of HCV transmission. Incorporating differing risk profiles associated with drug use may provide opportunities to further optimize and target HCV treatment and prevention strategies.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  clustering; cocaine; crack cocaine; distal outcome; hepatitis C virus; heroin; latent class analysis; phylogenetic

Mesh:

Year:  2017        PMID: 28719060      PMCID: PMC5743579          DOI: 10.1111/jvh.12758

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  45 in total

Review 1.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

2.  Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.

Authors:  Brendan Jacka; Tanya Applegate; Art F Poon; Jayna Raghwani; P Richard Harrigan; Kora DeBeck; M-J Milloy; Mel Krajden; Andrea Olmstead; Jeffrey B Joy; Brandon D L Marshall; Kanna Hayashi; Oliver G Pybus; Viviane Dias Lima; Gkikas Magiorkinis; Julio Montaner; Francois Lamoury; Gregory J Dore; Evan Wood; Jason Grebely
Journal:  J Hepatol       Date:  2016-02-26       Impact factor: 25.083

3.  Patterns of drug use, risky behavior, and health status among persons who inject drugs living in San Diego, California: a latent class analysis.

Authors:  Alexis M Roth; Richard A Armenta; Karla D Wagner; Scott C Roesch; Ricky N Bluthenthal; Jazmine Cuevas-Mota; Richard S Garfein
Journal:  Subst Use Misuse       Date:  2014-10-14       Impact factor: 2.164

4.  Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention.

Authors:  Kimberly Page; Meghan D Morris; Judith A Hahn; Lisa Maher; Maria Prins
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

5.  Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network.

Authors:  Li-Tzy Wu; Walter Ling; Bruce Burchett; Dan G Blazer; Chongming Yang; Jeng-Jong Pan; Bryce B Reeve; George E Woody
Journal:  Drug Alcohol Depend       Date:  2011-04-17       Impact factor: 4.492

6.  Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort.

Authors:  Joseph Cox; Emilie Maurais; Lina Hu; Erica E M Moodie; Stephanie Law; Nikki Bozinoff; Martin Potter; Kathleen Rollet; Mark Hull; Mark Tyndall; Curtis Cooper; John Gill; Sahar Saeed; Marina B Klein
Journal:  Drug Alcohol Depend       Date:  2014-01-30       Impact factor: 4.492

7.  "I inject less as I have easier access to pipes": injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed.

Authors:  Lynne Leonard; Emily DeRubeis; Linda Pelude; Emily Medd; Nick Birkett; Joyce Seto
Journal:  Int J Drug Policy       Date:  2007-05-01

8.  Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.

Authors:  Natasha K Martin; Matthew Hickman; Sharon J Hutchinson; David J Goldberg; Peter Vickerman
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

9.  The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis.

Authors:  François M J Lamoury; Brendan Jacka; Sofia Bartlett; Rowena A Bull; Arthur Wong; Janaki Amin; Janke Schinkel; Art F Poon; Gail V Matthews; Jason Grebely; Gregory J Dore; Tanya L Applegate
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

10.  Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

Authors:  Viviane D Lima; Ignacio Rozada; Jason Grebely; Mark Hull; Lillian Lourenco; Bohdan Nosyk; Mel Krajden; Eric Yoshida; Evan Wood; Julio S G Montaner
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more
  3 in total

1.  Injection and Sexual Behavior Profiles among People Who Inject Drugs in Miami, Florida.

Authors:  Teresa A Chueng; Hansel E Tookes; Megan McLaughlin; Angela M Arcaro-Vinas; David P Serota; Tyler S Bartholomew
Journal:  Subst Use Misuse       Date:  2022-06-10       Impact factor: 2.362

2.  Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore.

Authors:  Jada Hackman; Oluwaseun Falade-Nwulia; Eshan U Patel; Shruti H Mehta; Gregory D Kirk; Jacquie Astemborski; Stuart C Ray; David L Thomas; Oliver Laeyendecker
Journal:  Infect Genet Evol       Date:  2019-10-24       Impact factor: 3.342

3.  A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015.

Authors:  Sofia R Bartlett; Tanya L Applegate; Brendan P Jacka; Marianne Martinello; Francois Mj Lamoury; Mark Danta; Daniel Bradshaw; David Shaw; Andrew R Lloyd; Margaret Hellard; Gregory J Dore; Gail V Matthews; Jason Grebely
Journal:  J Int AIDS Soc       Date:  2019-02       Impact factor: 5.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.